Literature DB >> 7139974

Hypersecretion of a new corticosteroid, 18-hydroxycortisol in two types of adrenocortical hypertension.

S Ulick, M D Chu.   

Abstract

The most abundant substance in the urinary free steroid fraction of patients with primary aldosteronism has been identified as 18-hydroxycortisol. 18-hydroxycortisol is very likely an adrenocortical secretory product rather than a peripheral metabolite, since it is abundantly synthesized by aldosteronoma tissue slices. The biogenesis of 18-hydroxycortisol takes place from cortisol rather than from 18-hydroxycorticosterone; that is, 17 alpha-precedes 18-hydroxylation. Cortisol 18-hydroxylation appears to be unrelated to the two other types of adrenocortical hydroxylation at this position. The pathway is present to a small extent in the normal human adrenal cortex and is only moderately stimulated by ACTH. Cortisol 18-hydroxylation is markedly accentuated in two circumstances: in the aldosteronoma cell where its presence may serve to distinguish tumor from bilateral hyperplasia and in ACTH-stimulatable hyperaldosteronism where it represents the first qualitative steroid biochemical abnormality to be demonstrated and as such may be useful in diagnosis and genetic studies. The possible contribution of 18-hydroxycortisol to the severity of the clinical manifestations of mineralocorticoid excess in these two types of aldosteronism remains to be explored.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7139974     DOI: 10.3109/10641968209061640

Source DB:  PubMed          Journal:  Clin Exp Hypertens A        ISSN: 0730-0077


  17 in total

Review 1.  Primary aldosteronism: rare bird or common cause of secondary hypertension?

Authors:  M Stowasser
Journal:  Curr Hypertens Rep       Date:  2001-06       Impact factor: 5.369

2.  Studies on the origin of circulating 18-hydroxycortisol and 18-oxocortisol in normal human subjects.

Authors:  E Marie Freel; Loai A Shakerdi; Elaine C Friel; A Michael Wallace; Eleanor Davies; Robert Fraser; John M C Connell
Journal:  J Clin Endocrinol Metab       Date:  2004-09       Impact factor: 5.958

3.  Laboratory investigation of primary aldosteronism.

Authors:  Michael Stowasser; Paul J Taylor; Eduardo Pimenta; Ashraf H Al-Asaly Ahmed; Richard D Gordon
Journal:  Clin Biochem Rev       Date:  2010-05

Review 4.  Role of a disordered steroid metabolome in the elucidation of sterol and steroid biosynthesis.

Authors:  Cedric H L Shackleton
Journal:  Lipids       Date:  2011-08-27       Impact factor: 1.880

Review 5.  Steroid Profiling and Immunohistochemistry for Subtyping and Outcome Prediction in Primary Aldosteronism-a Review.

Authors:  Finn Holler; Daniel A Heinrich; Christian Adolf; Benjamin Lechner; Martin Bidlingmaier; Graeme Eisenhofer; Tracy Ann Williams; Martin Reincke
Journal:  Curr Hypertens Rep       Date:  2019-09-03       Impact factor: 5.369

Review 6.  Low-renin hypertension of childhood.

Authors:  J DiMartino-Nardi; M I New
Journal:  Pediatr Nephrol       Date:  1987-01       Impact factor: 3.714

7.  Disordered zonal and cellular CYP11B2 enzyme expression in familial hyperaldosteronism type 3.

Authors:  Celso E Gomez-Sanchez; Xin Qi; Elise P Gomez-Sanchez; Hironobu Sasano; Martin O Bohlen; Max Wisgerhof
Journal:  Mol Cell Endocrinol       Date:  2016-10-25       Impact factor: 4.102

8.  Dexamethasone-suppressible hyperaldosteronism: pathophysiology, clinical aspects, and new insights into the pathogenesis.

Authors:  F Fallo; N Sonino; M Boscaro; D Armanini; F Mantero; H G Dörr; D Knorr; U Kuhnle
Journal:  Klin Wochenschr       Date:  1987-05-15

Review 9.  Urine steroid profile as a new promising tool for the evaluation of adrenal tumors. Literature review.

Authors:  Marta Araujo-Castro; Pablo Valderrábano; Héctor F Escobar-Morreale; Felicia A Hanzu; Gregori Casals
Journal:  Endocrine       Date:  2020-11-21       Impact factor: 3.633

Review 10.  DIAGNOSIS OF ENDOCRINE DISEASE: 18-Oxocortisol and 18-hydroxycortisol: is there clinical utility of these steroids?

Authors:  Jacques W M Lenders; Tracy Ann Williams; Martin Reincke; Celso E Gomez-Sanchez
Journal:  Eur J Endocrinol       Date:  2017-09-13       Impact factor: 6.664

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.